Signet Financial Management LLC Reduces Stake in AbbVie Inc. $ABBV

Signet Financial Management LLC lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 39.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 25,094 shares of the company’s stock after selling 16,186 shares during the period. Signet Financial Management LLC’s holdings in AbbVie were worth $5,810,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of ABBV. Evolution Wealth Management Inc. acquired a new stake in AbbVie during the 2nd quarter worth about $26,000. Spurstone Advisory Services LLC acquired a new position in shares of AbbVie in the 2nd quarter valued at about $28,000. Redmont Wealth Advisors LLC purchased a new stake in shares of AbbVie in the third quarter worth about $41,000. Financial Gravity Companies Inc. acquired a new stake in AbbVie during the second quarter worth about $36,000. Finally, Delos Wealth Advisors LLC purchased a new position in AbbVie during the second quarter valued at approximately $39,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Down 1.7%

ABBV opened at $228.79 on Thursday. The firm’s fifty day simple moving average is $224.01 and its two-hundred day simple moving average is $221.68. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The company has a market cap of $404.36 billion, a price-to-earnings ratio of 96.95, a PEG ratio of 0.81 and a beta of 0.35.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The business had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the previous year, the company earned $2.16 earnings per share. The company’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on ABBV. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. JPMorgan Chase & Co. increased their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a report on Tuesday, November 4th. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research report on Tuesday, January 20th. Finally, Morgan Stanley raised their target price on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $251.56.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.